Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients

Breast

Volumn 19, Issue 3, 2010, Pages 246-248

  Koshy, Nebu ^a   Quispe, Dolly ^a   Shi, Runhua ^a   Mansour, Richard ^a   Burton, Gary V ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cisplatin and gemcitabine chemotherapy; Metastatic breast cancer; Triple negative

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MENOPAUSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; COHORT ANALYSIS; DRUG COMBINATION; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77953360941     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.02.003     Document Type: Article

References (18)

1. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumors. Nature 2000, 406:747-752.
2. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65.
3. Turner N., Tutt A., Ashworth A. Hallmarks of BRCAness in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
4. Turner N.C., Reis-Filho J.S. Basal-like breast cancer and the BRCA 1 phenotype. Oncogene 2006, 25:5846-5853.
5. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., et al. BRCA1 dysfunction in sporadic basal - like breast cancer. Oncogene 2007, 14:2126-2132.
6. Mersin H., Yildirim E., Berberoglu U., Gülben K. The prognostic importance of triple negative breast carcinoma. Breast 2008, 17:341-346.
7. Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer 2002, 3(Suppl. 1):24-29.
8. Garber J., Richardson A., Harris L., Miron A., Silver D., Golshan M., et al. Neo-adjuvant cisplatin(CDDP) in triple negative breast cancer. Breast Cancer Res Treat 2006, 100(Suppl. 1). Abstract 3074.
9. O' Shaughnessy J., Weckstein D., Vukejlja S., Mclntyre K., Krekow L., Holmes F., et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl. 1):S32. Abstract 308.
10. Sirohi B., Arnedos M., Popat S., Ashley S., Nerurkar A., Walsh G., et al. Platinum based chemotherapy in triple negative breast cancer. Ann Oncol 2008, 20:1-6.
11. Yi S., Uhm J., Cho E., Lee S., Park M., Jun H., et al. Clinical outcomes of metastatic breast cancer patients with triple negative phenotype who received platinum containing chemotherapy. J Clin Oncol 2008, 26(Suppl. 15):43s. Abstract 1008.
12. Chew H.K., Doroshow J.H., Frankel P., Margolin K.A., Somlo G., Lenz H.J., et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009, 27:2163-2169.
13. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
14. Carey L.A., Perou C.M., Livsay C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
15. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
16. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
17. O'Shaughnessy J., Osborne C., Pippen J., Yoffe M., Patt D., Monaghan G., et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27(Suppl. 18):793s. Abstract 3.
18. Tutt A., Robson M., Garber J.E., Domchek S., Audeh M.W., Weitzel J.N., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27(Suppl. 18):803s. Abstract CRA 501.